Physician profile
Lin Hao
NPI 1528325529
$5,149.81
in general payments reported to CMS, 2019-2025
29 companies · $61.81 in 2025
The $61.81 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $15.26 · 2021: $11.92 · 2022: $279 · 2023: $3,768 · 2024: $723 · 2025: $61.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,770 · Food and Beverage: $423 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,770.00 |
| Food and Beverage | $422.77 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $2,218.45 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $1,170.00 | 2023 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $419.85 | 2019-2024 | Imfinzi |
| Daiichi Sankyo INC. | $391.50 | 2022-2023 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $160.65 | 2024-2025 | Opdivo, Opdualag |
| Pfizer INC. | $124.09 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $118.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.14 | 2023-2024 | |
| Janssen Biotech, INC. | $66.06 | 2019-2025 | Rybrevant |
| Astellas Pharma US INC | $48.02 | 2020-2024 | Padcev |
| Myovant Sciences INC. | $42.16 | 2022 | |
| Puma Biotechnology, INC. | $35.14 | 2019 | |
| Dendreon Pharmaceuticals LLC | $32.27 | 2022 | |
| Mirati Therapeutics, INC. | $30.59 | 2024 | Krazati |
| Tersera Therapeutics LLC | $24.66 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $24.24 | 2024 | |
| Stemline Therapeutics INC. | $24.18 | 2025 | Orserdu |
| Servier Pharmaceuticals LLC | $22.94 | 2024 | |
| Eisai INC. | $22.64 | 2024 | |
| Array Biopharma INC | $20.13 | 2019 | |
| Amgen INC. | $13.73 | 2022 | |
| Abbvie INC. | $13.35 | 2019 | |
| Emd Serono, INC. | $13.06 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $12.57 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Genzyme Corporation | $11.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Hao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.